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Serious complications of any immunosuppressive regimen after
transplantation are either recurrent or de novo malignancies [1].
After orthotopic liver transplantation (OLT), performed on
patients presenting with hepatocellular carcinoma (HCC), recur-
rent malignancy occurs between 3% and up to 52%, depending
on the stage of the disease at the time of OLT. The majority of
recurrent carcinomas are detected more than one year after
OLT with a median survival of less than 10 months following
the diagnosis of the recurrence [2]. Therapeutic options are lim-
ited and the prognosis is poor for these recurrences even after
liver resection [3] and re-transplantation [4].
Rapamycin, which was discovered in 1965 on the Easter
Islands (Rapa Nui) from soil samples, belongs to a new class of
immunosuppressive drugs. Drugs like sirolimus, also known as
rapamycin (Rapamune, Wyeth) or everolimus (Certican, Nov-
artis) belong to inhibitors of the mammalian target of rapamycin
(mTOR) and simultaneously exhibit anti-proliferative and immu-
nosuppressive effects [5]. This protein is a central regulator of cell
metabolism, proliferation, and survival. It also modulates the
innate and adaptive immune responses by the regulation of den-
dritic and T-cells [6] (Fig. 1). These drugs could efﬁciently achieve
two goals at once: inducing tolerance of the graft and reducing
the risk of cancer. Recent data from in vitro and in vivo studies
suggest an import role of mTOR in HCC. Approximately 30–50%
of patients with HCC exhibit an activation of the mTOR pathway
as assessed by immunohistochemical analysis of phosphorylated
p70S6K, a direct downstream target of mTOR [7,8]. A temptingJournal of Hepatology 20
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Different studies have demonstrated better survival rates in
patients on sirolimus as compared to control liver recipients [9].
The signiﬁcance of these studies remains limited due to the small
number of patients included and the retrospective study design.
Toso, Kneteman, and colleagues [10] analyzed the impact of differ-
ent immunosuppressive regimens on the long-term survival of
recipients originally presenting with HCC. They included 2491
recipients originally presenting with HCC and a control group of
12,167 patients including those transplanted for diseases other
thanHCC.Thedatawere taken fromtheScientiﬁcRegistryof Trans-
plant Recipients (SRTR) database, which offers information about
all candidates listed for OLT, donors, and recipients in the United
States of America (www.ustransplant.org). In the HCC-group, 109
patients treated with sirolimus were compared to 2382 patients
treated with a different immunosuppressive protocol. Patients
displaying stable immunosuppression for at least 6 months
post-transplant were included in the univariate and multivariate
analysis. The two groups of patients with HCC on and off sirolimus
were comparable. The patients on sirolimus revealed an even
higherMELD score before OLT, excluding the risk of a confounding
bias based on a post-transplant kidney function. In this study, the
5-year survival of OLT recipients presenting with HCC was 83%
when receiving sirolimus compared to 69% in those patients trea-
ted with another regimen (HR 0.53, 95% CI: 0.31–0.92; p 60.05).
An improvement of almost 15% in the 5-year survival in
patients treated with an mTOR-inhibition regimen is impressive
and potentially of high clinical relevance. However, some ques-
tions arise when interpreting the data of this retrospective study.
What was the proportion of patients meeting the Milan criteria?
Was disease comparable regarding tumour classiﬁcation? Both
the univariate and multivariate analysis may be easily con-
founded by more aggressive tumour biology in the HCC-group
that had not received sirolimus. Several studies have shown that
tumour staging as well as grading and vascular invasion are the
most important factors affecting tumour recurrence in patients
receiving OLT for HCC [2,4]. Unfortunately, the study does not
provide this important information.
What was the recurrence rate in HCC-groups after OLT?
Although inhibition of mTOR prevents tumour recurrence in
in vitro and in vivomodels [7], the present data do not demonstrate
that sirolimus-based immunosuppression improves survival due
to anti-cancer effects. The study did not assess the main outcome
of interest, the recurrence-free survival, as the focuswas on overall11 vol. 54 j 182–183
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Fig. 1. Two different cell types affected by one drug. (A) Growth factors (e.g. insulin) usually activate tyrosine kinase receptors in the cells. This leads to the activation of
the PI3K-AKT-mTOR pathway. mTOR, in turn, regulates cellular processes like autophagy, cell growth, and angiogenesis, via further downstream targets. These cellular
functions are potentially disturbed in tumourgenesis and tumour progression. (B) In T-cells, the activation of the T-cell receptor leads to an mTOR-mediated cell cycle
progression and increased expression of IL2 and the IL2-receptor, leading to cell mediated immune-response. Drugs like sirolimus or everolimus inhibit this pathway at the
level of mTOR and may inhibit both the tumour cell growth and immune-response at once. (Simpliﬁed overview, for details see Thomson et al. [6].) Abbreviations: TK-
receptor, tyrosine-kinase receptor; PI3K, phosphoinositide-3 kinase; AKT, protein kinase B; mTOR, mammalian target of rapamycin; ATG, autophagy-related genes; p70S6K;
ribosomal protein S6 kinase; 4E-BP1, 4E-binding protein 1; HIF-1, hypoxia-inducible factor 1; NF-jB, nuclear factor ’kappa-light-chain-enhancer’ of activated B-cells; IL2,
Interleukin 2, IL2-R, Interleukin 2 receptor.
JOURNAL OF HEPATOLOGYsurvival. There is also no information about the median follow-up
after OLT. Therefore, the SRTR data may underestimate the HCC
recurrence rate due to under-reporting. In addition, the unknown
median follow-up limits the tempting conclusion that sirolimus
has oncological beneﬁts in the HCC population.
Is it possible to break the paradigm of effectively preventing
rejection with an immunosuppressive regimen and its inherent
risk of new or recurrent tumours? Toso and colleagues could not
answer this question conclusively, but they did provide important
clinical information about a representative and large cohort of
patients afterOLT. Thesedata areof great value todesigndeﬁnitive,
randomized controlled trials testing sirolimus in the HCC and non-
HCC population and may provide the ﬁnal answer.Conﬂict of interest
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